{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:15:04Z","timestamp":1793981704239,"version":"4.8.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.xcrm.2024.101393","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T15:33:57Z","timestamp":1706283237000},"page":"101393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Rishipathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Rapaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham M.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Banchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobe","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Varfolomeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruozhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domagoj","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Kiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chooi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Mellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomyseh","family":"Sanjabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Mariathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101393_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101393_bib4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2024.101393_bib5","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib6","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib7","article-title":"Role of immunotherapy in bladder cancer","volume":"26","author":"Rhea","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.xcrm.2024.101393_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2019.00264","article-title":"Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis","volume":"9","author":"Addeo","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1800275","article-title":"Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses","volume":"201","author":"Cubas","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101393_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101393_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101393_bib13","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib14","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101393_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101393_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101393_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2003.11.015","article-title":"Transcriptional regulation of antigen presentation","volume":"16","author":"van den Elsen","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101393_bib21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xcrm.2024.101393_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: an analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/annonc\/4.suppl_4.S41","article-title":"Advanced ovarian cancer. Carboplatin versus cisplatin","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","article-title":"Clinical pharmacokinetics of carboplatin","volume":"21","author":"van der Vijgh","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xcrm.2024.101393_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cac2.12139","article-title":"Diverse effects of chemotherapeutic agents on immune cell function and implications in immunochemotherapy","volume":"41","author":"Glorieux","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.xcrm.2024.101393_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s004320000169","article-title":"Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel\/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve","volume":"127","author":"Kern","year":"2001","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib28","article-title":"Cisplatin concentrations in long and short duration infusion: implications for the optimal time of radiation delivery","volume":"10","author":"Rajkumar","year":"2016","journal-title":"J.\u00a0Clin. Diagn. Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41419-019-1689-8","article-title":"ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation","volume":"10","author":"Gomes","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2024.101393_bib30","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1074\/jbc.M707568200","article-title":"ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis","volume":"283","author":"Pabla","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101393_bib31","first-page":"2275","article-title":"Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin","volume":"23","author":"Yazlovitskaya","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.xcrm.2024.101393_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101393_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8(+) T\u00a0cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101393_bib35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101393_bib36","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/db07-1499","article-title":"Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.xcrm.2024.101393_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101393_bib38","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaoncol.2021.5970","article-title":"Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the era of checkpoint inhibitors: a review","volume":"8","author":"Sadagopan","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib39","first-page":"5669","article-title":"Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response","volume":"53","author":"Blommaert","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib40","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/107327480000700214","article-title":"Strategies for combining chemotherapy and biotherapy in melanoma","volume":"7","author":"Buzaid","year":"2000","journal-title":"Cancer Control"},{"key":"10.1016\/j.xcrm.2024.101393_bib42","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma","volume":"16","author":"Legha","year":"1998","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib43","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.1999.17.3.968","article-title":"Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b","volume":"17","author":"Rosenberg","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101393_bib44","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101393_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/biom10010013","article-title":"Platinum derivatives effects on anticancer immune response","volume":"10","author":"R\u00e9b\u00e9","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.xcrm.2024.101393_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2024.101393_bib47","unstructured":"Bristol Myers Squibb. Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial. https:\/\/news.bms.com\/news\/details\/2023\/Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-Shows-Overall-Survival-and-Progression-Free-Survival-Benefit-for-Cisplatin-Eligible-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma-in-the-Phase-3-CheckMate--901-Trial\/default.aspx."},{"key":"10.1016\/j.xcrm.2024.101393_bib48","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-19-2959","article-title":"Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy","volume":"80","author":"Principe","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-1-4939-3578-9_15","article-title":"GMAP and GSNAP for genomic sequence alignment: Enhancements to speed, accuracy, and functionality","volume":"1418","author":"Wu","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101393_bib49","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101393_bib53","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101393_bib54","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101393_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003118","article-title":"Software for computing and annotating genomic ranges","volume":"9","author":"Lawrence","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.xcrm.2024.101393_bib52","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101393_bib55","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101393_bib56","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2024.101393_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:00:04Z","timestamp":1733223604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666379124000028"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101393","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101393"}}